期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
Chitosan:A Scaffold Biomaterial in 3D Bone Tissue Engineering and Its Biological Activities
1
作者 Gurung Chetali Nawaz Aamir +1 位作者 Udduttulla Anjaneyulu REN Peigen 《集成技术》 2025年第2期86-108,共23页
The ability to replicate the microenvironment of the human body through the fabrication of scaffolds is a significant achievement in the biomedical field.However,the search for the ideal scaffold is still in its infan... The ability to replicate the microenvironment of the human body through the fabrication of scaffolds is a significant achievement in the biomedical field.However,the search for the ideal scaffold is still in its infancy and there are significant challenges to overcome.In the modern era,the scientific community is increasingly turned to natural substances due to their superior biological ability,lower cost,biodegradability,and lower toxicity than synthetic lab-made products.Chitosan is a well-known polysaccharide that has recently garnered a high amount of attention for its biological activities,especially in 3D bone tissue engineering.Chitosan closely matches the native tissues and thus stands out as a popular candidate for bioprinting.This review focuses on the potential of chitosan-based scaffolds for advancements and the drawbacks in bone treatment.Chitosan-based nanocomposites have exhibited strong mechanical strength,water-trapping ability,cellular interaction,and biodegradability.Chitosan derivatives have also encouraged and provided different routes for treatment and enhanced biological activities.3D tailored bioprinting has opened new doors for designing and manufacturing scaffolds with biological,mechanical,and topographical properties. 展开更多
关键词 CHITOSAN 3D bioprinting bone tissue engineering SCAFFOLD tissue regeneration chitosan derivative
在线阅读 下载PDF
mRNA疫苗在药物开发的一些进展 被引量:1
2
作者 赵浩 柴德智 +2 位作者 蔡金旋 刘兰兰 张键 《集成技术》 2023年第5期62-75,共14页
在制药领域,严重急性呼吸综合征冠状病毒2型的暴发推动了mRNA疫苗的开发,并使其迅速发展。与其他形式的疫苗相比,mRNA疫苗生产过程简单,安全性优于DNA疫苗;mRNA编码的抗原易于在细胞中表达;mRNA无须在细胞核中转录,因此没有整合到宿主... 在制药领域,严重急性呼吸综合征冠状病毒2型的暴发推动了mRNA疫苗的开发,并使其迅速发展。与其他形式的疫苗相比,mRNA疫苗生产过程简单,安全性优于DNA疫苗;mRNA编码的抗原易于在细胞中表达;mRNA无须在细胞核中转录,因此没有整合到宿主基因组的风险。然而,mRNA疫苗也存在局限性,如可能产生过敏、肾衰竭等严重副作用,或在注射后可能迅速降解,或引起细胞因子风暴。因此,需解决mRNA疫苗的免疫原性及递送效率等问题。该文从mRNA疫苗的发展开始,重点讲述mRNA疫苗的分子设计、递送系统及临床现状,为后续mRNA疫苗的发展提供一些思考。 展开更多
关键词 mRNA疫苗 mRNA分子设计 递送系统
在线阅读 下载PDF
CMKLR1与chemerin及α-NETA复合体结构预测
3
作者 柴德智 蔡金旋 +1 位作者 于铭 张键 《集成技术》 2023年第5期51-61,共11页
他扎罗替尼诱导基因2(tazarotene-induced gene 2,TIG2)的产物chemerin是孤儿G蛋白耦联受体趋化因子样受体1(chemokine-like receptor 1,CMKLR1)的内源性配体。chemerin/CMKLR1信号系统在体内多组织器官发挥着重要的功能和作用。chemeri... 他扎罗替尼诱导基因2(tazarotene-induced gene 2,TIG2)的产物chemerin是孤儿G蛋白耦联受体趋化因子样受体1(chemokine-like receptor 1,CMKLR1)的内源性配体。chemerin/CMKLR1信号系统在体内多组织器官发挥着重要的功能和作用。chemerin的C端在体内被蛋白酶切后形成多种亚型,该文通过Alphafold2对chemerin的6种亚型进行结构预测与建模,并将其中有活性的3种形式与CMKLR1进行复合体建模,对复合体进行结合位点分析后,阐明不同活性形式的差异结合位点。此外,将CMKLR1的小分子拮抗剂2-(α-萘甲酰基)乙基三甲基碘化铵(2-(α-naphthoyl)ethyltrimethylammonium iodide,α-NETA)与CMKLR1进行对接,确定二者的相互结合位置。实验结果从蛋白质分子结构层面解释了两点:(1)具有活性的chemerin与CMKLR1的互作方式;(2)小分子拮抗剂α-NETA与CMKLR1的互作方式。研究内容将为CMKLR1的靶向药物设计提供理论依据和实验基础。 展开更多
关键词 趋化素 趋化素趋化因子样受体1(CMKLR1) 2-(α-萘甲酰基)乙基三甲基碘化铵(α-NETA) 复合体预测 分子对接
在线阅读 下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部